Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.
EMBO Mol Med
; 10(5)2018 05.
Article
in En
| MEDLINE
| ID: mdl-29650805
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Skin Neoplasms
/
Proteins
/
Drug Resistance, Neoplasm
/
Xenograft Model Antitumor Assays
/
MAP Kinase Kinase 1
/
Melanoma
Type of study:
Prognostic_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
EMBO Mol Med
Journal subject:
BIOLOGIA MOLECULAR
Year:
2018
Document type:
Article
Affiliation country:
Country of publication: